The second half of 2017 continues to move forward with appearances of author A. K. Buckroth.
August 24, 2017– HAS BEEN POSTPONED to Thursday, August 31, 2017…. Diabetes Talk: T1D vs. T2D, 1:30pm – 2:30pm3:30pm – 4:30pm ± in the Brookdale Senior Living Center, 7414 Stock Ranch Road in Citrus Heights, CA. Book give-away along with hand-outs regarding the international sign and color for diabetes, meal planning discussion/information, carbohydrates in alcohol beverages, the JDRF (Juvenile Diabetes Research Foundation) and more. Audience shares encouraged.
- Saturday, October 14, 2017 – Walnut Grove Library, 14177 Market St. P.O. Box 40, Walnut Grove, CA, 95690; 1:00pm – 5:00pm. “Authors Showcase” = Numerous authors will be available to share their books.
- Saturday, November 4, 2017 – Fair Oaks Library, 11601 Fair Oaks Blvd., Fair Oaks, CA, 95628, (916) 264-2770; 12:30pm – 5:00pm. “Authors Showcase” = Numerous authors will be available to share their books.
- Saturday, December 9, 2017 – North Highlands-Antelope Library, 235 Antelope Road, Antelope, CA, 95843, (916) 264-2920; 2:00pm – 5:00pm. “Authors Showcase” = Numerous authors will be available to share their books.
- Saturday, December 16, 2017 – Sylvan Oaks Library, 6700 Auburn Blvd., Citrus Heights, CA, 95621, (916) 264-2700; 2:00pm – 5:00pm. “Authors Showcase” = Numerous authors will be available to share their books.
- Book presentations with readings, autographing and sales will be available at all events. See you soon!
Continuing my ‘book marketing procedures,’ I am once again engaged in coordinating numerous “Authors Showcases” at local Sacramento County, California libraries. Promotion of my four award-winning books (www.mydiabeticsoul.com) is acceptable in such a free, and public venue. Encouragement and attention increases in such a familiar setting with numerous author participants and the general public visitors. Libraries are happy places.
As a ‘free-agent,’ sole-proprietor, self-published author, distribution and supply of my books is up to me and only me. When I began this trek in 2010, it was new to me, a bit frightening, unfamiliar. Thanks to my Masters Degree program (University of Pheonix, 1999), I gained the confidence required with public speaking. Thanks to a personal friend, also a self-published author, for leading me to my first writers meeting and club, I joined and became not only acquainted with other writers, published and unpublished, but my yearly membership lasted nine years leading me to marketing and promotional venues for all its members.
I like to think I help the general public become aware of my books (subject matter is T1D – Type One Diabetes) and their subject matter, the cost of each book and where to find them. Along the way, many other authors are consistently invited to participate to do the same. This process of multiple participant invitations continues to be more comfortable for me, having another person, specifically and author or two, to share in these experiences. It’s happy work.
For instance, an upcoming “Authors Showcase” with twenty authors is taking place at the Carmichael, California Library on Saturday, August 5, 2017, between 1 & 4pm. Other such events are in the works as well. Twenty individual authors, coming together in one place, most having the same dream as I – to promote out works, speak to individuals about out artistic values and beliefs – the whos, whats, whens, wheres, hows, and how muches involved in such a career. After all, writing is an individual personal art.
Libraries are free, comfortable, accommodating, safe, and easily accessible.
Other book marketing venues – with or without a price tag – have been city and country fairs with or without my supplying a personal E-Z up (tent); private speaking engagements in Church (Holy House) basements; and Assisted/Independent Living Centers where the residents are absolutely thrilled to listen about my books. All it takes is a little time for research location of resources, a hone call, and your in!
My next marketing venture is to gather individual writers from separate groups/clubs to join in an event. With numerous writing groups and clubs in this area, I wouldn’t think the opportunity would be too difficult. There is the beloved NCPA (Northern California Publishers and Authors Organization) CAW (California Writers), GCW (Gold Country Writers), SSWC (Sacramento Suburban Writers Club), SIC (Sisters In Crime), and others. This twinkling idea will grow – that’s how I work, with my brain. Heck, it’s appealing to me, encouraging, insightful, happy, especially when others are involved.
A. K. Buckroth
Cell Conversion Could Be a Change for the Better
Can the loss of functional beta cell mass in T1D be reversed to restore insulin production? That is a fundamental question for those working to eliminate the disease; and JDRF is supporting research that could provide some answers.
Unlike some other cells in our bodies, insulin-producing beta cells don’t replicate readily, especially as we age. That’s a problem for researchers who are working to cure T1D by rebuilding functional beta cell mass lost to autoimmune attacks. But some investigators have noticed that, with the right encouragement, other islet cells can change identity and take on the characteristics of beta cells, including insulin production. JDRF is supporting several projects seeking to exploit that ability, hoping to regenerate beta cell mass. Two JDRF-funded investigators recently announced they’d found ways to chemically stimulate pancreatic alpha cells—the cells that normally produce glucagon—to change into insulin-producing beta-like cells. French researcher Patrick Collombat, Ph.D., found that GABA, a naturally occurring chemical and common dietary supplement, triggers the conversion of mouse alpha cells into beta-like cells. Treating diabetic mice with GABA fully restored beta cell mass and reversed their diabetes, and human islets transplanted into mice appeared to respond in the same way as the mouse islets. Investigator Stefan Kubicek, Ph.D., at the Austrian Academy of Sciences realized similar results using a type of FDA-approved anti-malarial drugs called artemisinins. These results suggest it may be possible to “retrain” alpha cells that continue to survive in the pancreas of a person with T1D into insulin-producing cells, a critical step toward a cure.
Next steps for both investigators include working to better understand the processes and mechanisms underlying the alpha-to-beta cell changes, which could help identify improved compounds that are able to trigger the same alterations. Continued research could also enable them to determine how best to use these compounds to treat the disease. They’ll also investigate whether the changed cells can reliably reverse mouse models of T1D. Most importantly, these compounds, which are already in use in humans, may be moved quickly into clinical testing for the treatment of T1D. Restoring functional beta cell mass and renewing the body’s ability to produce insulin is a high priority for JDRF because it would reduce or eliminate the daily burdens and hazards of managing blood-glucose levels. Even partial restoration or maintenance of beta cell function could offer significant benefits to people with T1D, including slowing or preventing progression of the disease, reduced insulin requirements, improved glucose control and a lower risk of complications. Find out more about JDRF’s Beta Cell Restoration Program at jdrf.org.
Why is this important?
Restoring the body’s ability to produce insulin will enable people with T1D to more easily manage their blood-glucose levels and may ultimately provide a cure for the disease. To do that, it’s necessary to have a sufficient number of functional beta cells, whether they’re naturally produced, chemically transformed or implanted. Once we find ways to restore and protect functional beta cell mass, the burdens, limitations and fears associated with T1D become things of the past.
About the Author:
“Mbolonzi Mbaluka understands. A Kenyan living with type 1 diabetes, he has had to skip insulin injections, sometimes because he could not afford the cost and sometimes because local hospitals ran out of stock. A fellow Kenyan patient recently died after going two months without insulin, which in many countries can cost up to 50 percent or more of the average income. For example, in Brazil, insulin and supplies can cost over 80 percent of an average income. “The insulin and the equipment together are just not affordable for many,” Mbaluka says.
“Insulin is a pancreas-created hormone that allows the body to absorb and deploy sugar from consumed food. For people with type 2 diabetes, the pancreas struggles to keep up with the body’s insulin demand, either because the pancreas is not producing enough or because the body has developed insulin resistance. For persons with type 1 diabetes, their body’s immune system has damaged or destroyed the insulin-producing cells in the pancreas. A lack of insulin causes blood sugar levels to rise, damaging the heart, kidneys, eyes, and nerves. Over 400 million people globally have diabetes. Lack of widespread testing makes it hard to apportion the percentages between type 1 and type 2, but the majority of those people have type 2 diabetes. And according to some estimates, half of those who need insulin cannot reliably get access to it. People with type 2 diabetes often need to take insulin shots on a temporary or permanent basis. For people with type 1 diabetes, the equation is much more uniform, and more stark: they must inject insulin in order to stay alive.
“The discovery of insulin in the 1920s by a University of Toronto research team is one of history’s great pharmaceutical success stories. Orthopedic surgeon Frederick Banting and medical student Charles Best were able to extract insulin from an animal pancreas and inject it into a diabetic human, a groundbreaking advancement that earned Banting the Nobel Prize. Suddenly, a fatal disease became a survivable, chronic condition—as long as the insulin was available to the patient.
“The researchers were ideologically opposed to monopoly patenting of biomedical discoveries, but they were eager to see that wide distribution begin as soon as possible. And so, the researchers took out a patent for insulin, which they promptly sold to the university for $1 each. The plan was for the university to partner with pharmaceutical companies that were prepared to mass produce and distribute insulin. (A few decades later, Jonas Salk would famously refuse to patent the polio vaccine.)
“The researchers who discovered insulin were ideologically opposed to monopoly patenting of biomedical discoveries.
“For a while, the plan worked. Insulin became widely available and affordably priced. It was even improved upon. Innovations reduced the frequency of needed injections. Soon, the first human insulin and then synthetic insulin, known as analogues, replaced the original animal-extracted version. Yet those changes also caused problems. Each improvement allowed for corporations to take out their own patents on the new versions, and the price began to increase. The far-cheaper former versions of insulin, which experts generally agree were not significantly less effective than the enhanced iterations, disappeared from the market.
“Although the changes in insulin over the years have brought some benefits to patients, some experts say that the insulin producers’ tactics have corrupted the original public health vision of the medicine’s inventors. “I don’t think it takes a cynic such as myself to see most of these (insulin) drugs are being developed to preserve patent protection,” Harvard Medical School professor David Nathan told The Washington Post. “The truth is they are marginally different, and the clinical benefits of them over the older drugs are zero.”
“Yet the three main manufacturers of insulin—Eli Lilly, Sanofi Aventis, and Novo Nordisk—have dramatically raised prices on the newest versions. A 2016 study published in the Journal of the American Medical Association showed that the cost of insulin in the U.S. almost tripled between 2002 and 2013, and prices have continued to climb since. A U.S. patient’s out-of-pocket cost for a month’s supply of Eli Lilly’s Humalog can be over $400.
“For the drug companies, insulin is a hugely profitable product. Although manufacturers keep the cost of insulin production a tightly-guarded secret, U.S. prices are likely hundreds of times higher than the expense of making the drug. With annual revenues of $31 billion and growing, insulin is one of the highest-grossing medicines in the global market.
“But for patients who are dependent on insulin, its cost is creating a crisis—and not just in low-income countries but also in the comparatively wealthy United States. Increasingly, a lack of insurance coverage for the medicine or high-deductible coverage leaves people with diabetes paying as much as half their income for insulin. Patients report skipping doses, injecting expired insulin, and even starving themselves to control their blood sugar. Some patients are intentionally allowing themselves to slip into the life-threatening state of diabetic ketoacidosis just so they can obtain free insulin samples from emergency rooms. Not surprisingly, physicians report seeing more patients in distress because they can’t afford their insulin.
“Americans with type 1 diabetes are particularly anxious over the likely repeal of the Affordable Care Act, which protects them against coverage denials because of pre-existing conditions and against lifetime caps on coverage. Amy Leyendecker, who lives in Elizabethtown, Kentucky, currently has most of her insulin and equipment costs paid by insurance provided by her husband’s employer. But she has been without health insurance before, and is anxious about what may happen when her husband retires in a post-ACA world. “I have a five-month stash of insulin in my refrigerator that a friend brought in from outside the U.S.,” she says. “This is life-and-death for me.”
“THE PUSH FOR LOWER PRICING”
“Among those fighting for more affordable insulin is T1International. Elliott and Mbolonzi Mbaluka are active members. The group’s founder and director, Elizabeth Rowley, began the organization as a blog, but she quickly discovered that there was a global population of persons living with type 1diabetes eager to connect—and to speak out. One core purpose of the group is to provide a forum for those patient voices. “There are a lot of difficult challenges people with type 1 struggle with,” Rowley says. “And number one among those is that the prices for insulin and equipment are just far too high.”
“Rowley and her colleagues try to channel widespread frustration into focused activism. T1International’s detailed toolkit for advocacy includes global case studies of successful campaigns for better insulin access, tactical guidance, and tips on dealing with elected officials—“Sometimes you have to make the politician think it was their idea.” They collect data on insulin and supply costs, publish accounts of patient experiences worldwide, and even steer U.S. patients toward the attorneys who have filed a class action suit against the insulin manufacturers. That lawsuit, in the U.S. District Court in Massachusetts, alleges price collusion among the three major manufacturers, citing years of remarkably similar price increases by Eli Lilly, Sanofi, and Novo Nordisk.
“T1Inernational’s support of that litigation, and its outspoken criticism of insulin pricing, put it squarely at odds with the pharmaceutical industry. That also makes the group different from most patient advocacy groups. Groups including cancer patient groups and allergy and asthma patient groups have come under criticism for not speaking out in response to drug pricing issues. Most even declined to weigh in even during the recent high-profile Epi-Pen and Martin Shkreli “pharma bro” debates, in which triple-digit drug price increases led to public outcry and Congressional hearings.
“In fact, patient groups often vigorously support the pharma industry agenda, while at the same time receiving significant pharma funding. A 2016 report by the U.S. advocacy group Public Citizen revealed that at least three-quarters of the patient groups who actively opposed an Obama administration proposal to reduce Medicare drug expenditures received pharma industry donations. Another study showed that over 90 percent of patient groups participating in a discussion of FDA drug approval reform were pharma-funded. Most patient groups that opposed California’s 2016 ballot measure to regulate the medicine prices paid by state government proved to be heavily funded by pharmaceutical corporations.
“Not surprisingly, access to medicines advocates report that patient group representatives privately admit that they won’t speak out on drug pricing for fear of losing state funding. That fear is well-founded. The U.S. National Multiple Sclerosis Society endured push-back from its pharma funders when it dared to mention concerns over the cost of multiple sclerosis drugs that average $78,000 annually, a 400 percent increase in little over a decade.
“Patient group representatives privately admit that they won’t speak out on drug pricing for fear of losing state funding.
“T1International refuses on principle to accept pharma industry donations. “Even if they don’t force you to take certain positions, it is human nature not to want to bite the hand that feeds you,” Rowley says. But that choice has implications. Although pharma-funded organizations such as the International Diabetes Federation and the American Diabetes Association are well-staffed, T1International gets by with an all-volunteer workforce, anchored by Rowley’s 40-plus hours of unpaid labor each week.
“She and other volunteers continue to spend those hours ratcheting up the pressure on lawmakers and companies to address insulin pricing. They push for congressional hearings on the alleged industry collusion, expose the limitations of well-publicized corporate drug donation programs, and build a social media community around the theme of #insulin4all. And they are giving voice to the argument that essential medicines should be once again a public good, not a for-profit commodity. “It is a tragedy that a drug like insulin, invented by people who were motivated by a goal of access to all, is so clearly unavailable to so many,” Elliott says. “People are dying, and that is a status quo no one can defend.” “
…from “Please Understand Me” by Keirsey & Bates
- “Extroverted INtuitive Feeling Judging, known as “ENFJs,” are outstanding leaders of groups and growth groups. They have the charming characteristic of seeming to take for granted that they will be followed, never doubting that people will want to do what they suggest. And, more often than not, people do, because this type has unusual charisma. ENFJs place a high value on cooperation from others and are most willing to cooperate themselves.”
- “INFJs focus on possibilities, think in terms of values and come easily to decisions. The small number of this type (1%) is regrettable, since INFJs have an unusually strong drive to contribute to the welfare of others and genuinely enjoy helping their fellow men [or women]. This type has great depth of personality; they are themselves complicated, and can understand and deal with complex issues and people.” https://www.verywell.com/infj-introverted-intuitive-feeling-judging-2795978
- “For ENFPs (https://en.wikipedia.org/wiki/ENFP), nothing occurs which does not have some significance, and they have an uncanny sense of the motivations of others. This gives them a talent for seeing life as an exciting drama, pregnant with possibilities for both good and evil. This [personality] type is found in only about 5% of the general population, but they have great influence because of their extraordinary impact on others.”
- “INFPs (https://www.verywell.com/infp-a-profile-of-the-idealist-personality-type) represent a calm, pleasant face to the world and are seen as reticent and even shy. Although they demonstrate a cool reserve toward others, inside they are anything but distant. They have a capacity for caring which is not always found in other types. They care deeply–indeed, passionately– about a few special persons or a cause. One word that captures this type in idealistic. At times, this characteristic leaves them feeling isolated, especially sin INFPs are found in only 1% of the general population.”
- “If one word were used to capture ENTJs style, it would be commandant (https://en.wikipedia.org/wiki/ENTJ). The basic driving force and need of ENTJs is to lead, and from an early age they can be observed taking over groups. This type is found in approximately 5% of the total population. They have a strong urge to give structure wherever they hare–to harness people to distant goals.”
- “INTJs are the most self-confident of all they types, having “self-power” awareness. Found in about 1% of the general population, the INTJs live in an introspective reality, focusing on possibilities, using thinking in the form of empirical logic, and preferring that events and people serve some positive use.” (https://www.verywell.com/intj-introverted-intuitive-thinking-judging-2795988)
- “ENTPs wish to exercise their ingenuity in the world of people and things. Found in about five out of every hundred people, ENTPs extravert intuition; thus they deal imaginatively with social relationships as well as physical and mechanical relations. They are very alert to what is apt to occur next, and always sensitive to possibilities.” (https://www.verywell.com/intj-introverted-intuitive-thinking-judging-2795988.)
- “INTPs exhibit the greatest precision in thought and language of all the types; they tend to see distinctions and inconsistencies in thought and language instantaneously. The one work which captures the unique style of INTPs is architect–the architect of ideas and systems as well as the architect of edifices. This type is found in only 1% of the population and therefore is not encountered as frequently as some of the other types.” (https://en.wikipedia.org/wiki/INTP.)
- “ESTJs are very much in touch with the external environment. They know their community and usually are pillars of strength. The best adjective to describe ESTJs would be responsible. The represent about 13% of the general population.” (https://www.16personalities.com/estj-personality.)
- “ISTJs are characterized by decisiveness in practical affairs, are the guardians of time-honored institutions, and, if only one adjective could be selected, dependable would best describe this type which represents about 6percen of the general population.” (http://www.personalitypage.com/ISTJ.html.)
- “ESFJs, the most sociable of all types, are energized by interactions with people, tending to idealize whatever of whoever they admire. Harmony is a key to this type, which is represented in about 13 percent of the general population.” (http://www.truity.com/personality-type/esfj.)
- “Six out of every one hundred people are ISFJs. Here the primary desire is to be of service and to minister to individual needs. ISFJs carry a sense of history, a sense of continuity with past events and relationships. Traditions and the conservation of resources are valued highly. …ISFJs believe work is good, play must be earned.” (http://www.personalitypage.com/ISFJ.html.)
- “ESTPs are men and women of action. When someone of this personality is present, things begin to happen. The lights come on, the music plays, the game begins. And a game it is for the ESTP, the outstanding entrepreneur, the international diplomat, the conciliator, and the negotiator par excellence. Approximately 13% of the general population are of this extraverted, sensing, thinking, perceiving type, and if only one adjective could be used to describe ESTPs resourceful would be an apt choice.” (https://www.16personalities.com/estp-personality.)
- “ESFPs radiate attractive warmth and optimism. Smooth, witty, charming, clever, voluble, and open to the environment–this describes ESFPs who, like ESTPs, represent about 13% of the general population. They are great fun to be with and are the most generous of all the types. Performer would be the word which best describes an ESFP.” (https://www.verywell.com/esfp-extraverted-sensing-feeling-perceiving-2795984.)
- “Just as impulsive as other SPs, the ISTP’s life is artful action–and action is end in itself. Action for the ISTP is more gratifying if it is born of impulse rather than of purpose. If the action is in the service of an end or aim, let the aim look out for itself; it cannot be allowed to influence execution. The act is self-directed, self-leading, containing its own imperatives which are egalitarian an can be fiercely loyal to “brothers,” but they can also be fiercely insubordinate, seeing hierarchy and authority as unnecessary and even superfluous.’ (https://www.verywell.com/istp-introverted-sensing-thinking-perceiving-2795993.)
- Although all SPs (Sensuous Performers) are artisans in their nature, they usually do not pursue their artistry with the same devotion to grace and adornment as the ISFP. For whatever reason, the ISFP seems more inclined to the “fine arts” than the other SPs; so when an especially gifted composer, painter, or dance shows up, he or she, more frequently than not, possesses the character of the ISFP. Beethoven, Toscanini, Rembrandt, and Nijinski, as shown by typohistorical research, were clear-cut ISFPs. But the ISFP temperament is very difficult to observe, even in the great artists, and so ISFP is probably the most misunderstood of all the types.” (https://www.16personalities.com/isfp-personality.)
From A. K. Buckroth, it’s fun to know, it’s fun to learn! I hope you enjoyed reading this book excerpt. I enjoyed sharing it with my readers. Just sayin’…. #buckroth
JDRF Celebrates Historic Artificial Pancreas Success Bringing Life-changing Benefits to People with Type 1 Diabetes
FDA Approves Medtronic Hybrid Closed Loop System
“On September 28, 2016, the type 1 diabetes (T1D) community reached a major breakthrough with the FDA’s approval of the Medtronic hybrid closed loop system. The system is the first ever approved to automate the dosing of insulin to reduce high blood sugar levels.
“The new Medtronic MiniMed 670G artificial pancreas system is a life-changing breakthrough that allows people with T1D to stay closer to their target blood sugar levels more consistently. JDRF celebrates a decade of dedicated partnership, collaboration, funding and advocacy that have made it possible to reach this landmark goal.
“Today’s announcement is a historical achievement for JDRF and the entire T1D community. After years of laying the ground work, this life-changing breakthrough is a true testament to the reason JDRF exists, which is to accelerate ways to cure, prevent and treat this disease,” said Derek Rapp, JDRF President and CEO.
“The artificial pancreas system is designed to use Medtronic’s MiniMed 670G insulin pump, 4th-generation sensors and a control algorithm to automate basal insulin delivery to maximize the time glucose levels are in a healthy range throughout the day and night. The system is fully integrated between the pump and sensor, with no need for a separate smartphone or CGM monitor. The AP system will give many people with T1D new freedom and peace of mind as for the first time, they may be able to sleep through the night without periodically waking up to check and manage their blood glucose levels.
“A study recently published in the Journal of the American Medical Association (JAMA) found that on the 670G system, 124 patients had no episodes of severe hypoglycemia or ketoacidosis over 12,389 patient days.
“Further, the 670G system kept people with T1D within their desired blood sugar range 73.4% of the time, vs. 67.8% without the system. At night, the most dangerous time for blood sugar highs and lows, the difference was even more pronounced, 76.4% in range vs. 67.8% without the system.
“Les Hazelton, who participated in one 670G trial, explains, “Bottom line: I feel better today and since going into this study, than at any point after I was diagnosed — physically, emotionally, confident in how I’m managing my diabetes. You can get emotional about it. On the good days, if there are enough of them, you recall how you feel — that’s how I feel almost every day now. That’s what it has done to help me.”
“JDRF has been pivotal in developing and pursuing its Artificial Pancreas Project since 2006. In less than 10 years, JDRF transformed the AP field, working closely with numerous partners, researchers and companies to overcome the challenges that prevented AP technology from moving forward. Together, JDRF, the Helmsley Charitable Trust, and the National Institutes of Health’s Special Diabetes Program have funded hundreds of millions of dollars in research across the globe to develop and test sophisticated computer algorithms and components needed for the AP systems. JDRF developed a roadmap to create successively advanced versions of the AP, which has been embraced by manufacturers to guide their own R&D programs. JDRF has also worked with the leadership of the Senate and House Diabetes Caucus and other allies in Congress to provide research funding through the Special Diabetes Program and overcome obstacles that could delay delivery of AP systems to people with T1D.
“JDRF funded early artificial pancreas research as part of its hypoglycemia prevention efforts, and in 2006, JDRF launched the Artificial Pancreas Consortium, made up of leading endocrinologists, mathematicians, and engineers at top research institutions in the U.S. and Europe. JDRF and the FDA partnered to proactively address regulatory obstacles, leading to the 2012 FDA guidance for artificial pancreas device systems, which provided a regulatory pathway for system commercialization.
“This month’s huge leap forward would not have been possible without the support of JDRF’s many partners, notably, the Helmsley Charitable Trust, and everyone in the T1D community who has contributed their time, energy and financial support over the last decade.
“But while this is a breakthrough, it is not the end goal. JDRF remains committed to the search for a cure and to ensure people are healthier and have a reduced diabetes management burden until we get there.
“This is a fantastic step forward, but we are not done, JDRF will continue supporting other artificial pancreas advancements and advocating for broad access to this life-changing technology,” said JDRF Chief Mission Officer Aaron J. Kowalski, PhD. “Next generation systems are in the pipeline that could provide even better outcomes with less burden. And our work will not be finished until we cure and prevent T1D.
“More than 10 years of hard work have brought us to this point. In the past decade, JDRF has invested more than $116 million in diverse artificial pancreas research projects, with the goal of aiding the development of multiple, reliable treatment choices for people living with T1D. With continued collaboration and support, imagine what we can accomplish next!”